Adams Seeks to Develop New Prescription Adult Cough Products Using
Lipocine's Proprietary Lip'ral(TM) Technologies
CHESTER, N.J. and SALT LAKE CITY, Sept. 19 /PRNewswire-FirstCall/ -- Adams Respiratory Therapeutics, Inc. (Nasdaq: ARxT) and Lipocine Inc., a privately- held, leading drug delivery company that uses clinically validated proprietary technologies to address key unmet drug delivery and therapeutics needs, today announced that they have entered into a license and collaboration agreement to develop new prescription adult cough products.
Commenting on the agreement, COO Robert D. Casale said, "This collaboration with Lipocine provides Adams with access to an additional proprietary platform technology and fits with our strategy of taking established compounds and adding increased functionality to create patent- protected, value-added products. The products developed through this collaboration could offer doctors a non-narcotic prescribing option to treat cough with an enhanced dosing regimen. In addition, these products will help Adams compete in the $1.1 billion prescription cough and cold market in the United States."
"Given the large and growing size of the respiratory market, and how patients can benefit from enhanced dosage forms and regimens, we are very pleased to partner with Adams, a company highly respected for its commercialization accomplishments," said Dr. Mahesh Patel, president and CEO of Lipocine Inc.
Lip'ral(TM) and Lip'ral(TM)-SSR are clinically proven oral delivery
technologies for water insoluble drugs that improve absorption and can be
extended to enable controlled release of insoluble drugs and drugs with pH-
sensitive solubility. Multiple patents h
|SOURCE Adams Respiratory Therapeutics, Inc.|
Copyright©2007 PR Newswire.
All rights reserved